Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.
暂无分享,去创建一个
F. Simons | J. Menten | J. Leff | A. Teper | B. Sekerel | G. Aristizábal | J. Villa | B. W. Lee | A. Schuster | J. Pérez-Frías | B. Lyttle | W. Laessig | B. W. Lee | Jonathan A. Leff | F.Estelle R. Simons | Jose R. Villa | Bee W. Lee | Alejandro M. Teper | Brian Lyttle | Gustavo Aristizabal | Wolfgang Laessig | Antje Schuster | Javier Perez-Frias
[1] R. Pauwels,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.
[2] N Franklin Adkinson,et al. Long-term effects of budesonide or nedocromil in children with asthma. , 2000, The New England journal of medicine.
[3] D. Stempel. Montelukast added to inhaled beclomethasone in treatment of asthma. , 2000, American journal of respiratory and critical care medicine.
[4] H. Bisgaard,et al. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). , 2000, Respiratory medicine.
[5] S. Shrewsbury,et al. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.
[6] C. White,et al. Exhaled nitric oxide before and after montelukast sodium therapy in school‐age children with chronic asthma: A preliminary study , 1999, Pediatric pulmonology.
[7] H. Bisgaard,et al. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. , 1999, American journal of respiratory and critical care medicine.
[8] E. Israel,et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients , 1999, BMJ.
[9] L. Boulet,et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. , 1999, The European respiratory journal.
[10] F. Simons,et al. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. , 1998, Journal of Allergy and Clinical Immunology.
[11] S. Malozowski,et al. Comparison of beclomethasone, salmeterol, and placebo in children with asthma. , 1998, The New England journal of medicine.
[12] J. Kemp,et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. , 1998, The Journal of pediatrics.
[13] S. Szefler,et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. , 1998, The Journal of pediatrics.
[14] J. Bernstein,et al. Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind Trial , 1998 .
[15] J. Donahue,et al. Inhaled Steroids and the Risk of Hospitalization for Asthma , 1998 .
[16] F. Simons,et al. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. , 1997, The New England journal of medicine.
[17] K. Chung,et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. , 1997, The New England journal of medicine.
[18] Third Expert Panel on theDiagnosis,et al. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .
[19] J. Baker,et al. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. , 1997, European journal of biochemistry.
[20] S. Pedersen,et al. Budesonide treatment of moderate and severe asthma in children: a dose-response study. , 1995, The Journal of allergy and clinical immunology.
[21] J. Oates,et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. , 1994, American journal of respiratory and critical care medicine.